Sign In
Buy IBB
$189.55
-2.51 (-1.31%)
At Close: Jul 13, 2026
Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?
03:30pm, Sunday, 12'th Jul 2026
First Trust NYSE Arca Biotechnology Index Fund offers a more concentrated portfolio with only 30 holdings compared to the 248 positions in iShares Biotechnology ETF iShares Biotechnology ETF is the la
IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy?
06:41am, Friday, 10'th Jul 2026
The iShares U.S. Pharmaceuticals ETF (IHE) offers a lower expense ratio and a significantly higher dividend yield than the iShares Biotechnology ETF (IBB). IBB offers broader diversification, with 248
3 Healthcare ETFs to Own in a Choppy Stock Market
02:04pm, Monday, 06'th Jul 2026
Healthcare stocks are attractive in a choppy market. These funds, focusing on the broader sector, drugmakers, and biotechs, are worth a look.
Investors Are Rotating Into Healthcare. Here's Why.
03:55pm, Thursday, 02'nd Jul 2026
Janus Henderson portfolio manager Dan Lyons discusses why he sees opportunities for market outperformance in the healthcare sector as innovations in biotechnology, pharmaceuticals and medical devices
SPDR Health Care ETF Tops iShares Biotech in Long-Term Returns
07:45am, Thursday, 02'nd Jul 2026
State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio of 0.08% compared to 0.44% for iShares Biotechnology ETF. iShares' ETF provides concentrated exposure to 248
Big Pharma's Looming Patent Cliff Period And How It Is Trying To Address It
05:00pm, Monday, 29'th Jun 2026
Big pharma's patent cliff risk is somewhat overstated, as layered IP and litigation often extend exclusivity beyond headline expiries. Incremental innovation—new formulations, improved delivery, and
Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
12:11pm, Monday, 29'th Jun 2026
LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
07:20am, Monday, 29'th Jun 2026
A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market.
Biotech's Silent Resurgence (5-Year Base Breakout)
05:21pm, Tuesday, 23'rd Jun 2026
The biotech sector's fundamentals are shifting rapidly-and the smartest money on Wall Street is already quietly rotating into the sector.
Biotech ETFs Gain Momentum via AI Drug Discovery & Surging M&A
04:34pm, Tuesday, 23'rd Jun 2026
The biotechnology sector has broken out of its multiyear bear market. As macroeconomic headwinds moderate and regulatory environments stabilize, biotech ETFs are surging.
Chip Bloodbath Hits Nasdaq 100 As South Korea Plunges: Stock Market Today
12:45pm, Tuesday, 23'rd Jun 2026
U.S. stocks splintered Tuesday as a violent global sell-off in semiconductor shares hammered the Nasdaq, even as a rotation into defensive sectors and small caps kept the Dow Jones in positive territo
Should You Invest in the iShares Biotechnology ETF (IBB)?
07:20am, Monday, 22'nd Jun 2026
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on Febru
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
01:00am, Tuesday, 16'th Jun 2026
Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-trac
IBB: Space Stocks And AI Stealing The Risk-On Show In 2026
03:52pm, Monday, 15'th Jun 2026
I reiterate a Hold rating on the iShares Nasdaq Biotechnology ETF, citing modest valuation but lackluster momentum and unfavorable market themes. IBB lags the S&P 500 YTD and faces headwinds as specul
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
07:14am, Thursday, 11'th Jun 2026
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect
